Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trade/Invest with Options Jerry a Point & Figure Chartist -- Ignore unavailable to you. Want to Upgrade?

To: GREENLAW4-7 who wrote (3794)	9/27/2001 8:14:46 AM
From: 2MAR$	Read Replies (1) \| Respond to of 5893

well I just made 40% shorting SONS from last night... I was calling shorts all thru august greenlaw ... especially in the GSO.X was everybody asleep?

To: GREENLAW4-7 who wrote (3794)	9/27/2001 9:49:50 AM
From: Frederick Langford	Read Replies (1) \| Respond to of 5893

Myriad Genetics to Launch MELARIS(TM) - a Predictive Medicine Test For Melanoma - Hereditary Skin Cancer Test Is Myriad's Fourth Commercial Product - SALT LAKE CITY, Sept. 27 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that it plans to launch a predictive medicine test for malignant melanoma, a deadly form of skin cancer, in November 2001. The test, named MELARIS(TM), is used to assess an individual's risk of developing melanoma based on the detection of inherited mutations in the p16 (CDKN2A) gene. Scientists at Myriad Genetics discovered that the p16 gene is involved in the genesis of many types of cancer, including melanoma, leukemia, lymphoma and cancers of the breast, ovary, bone, brain and bladder. The p16 gene functions as a molecular brake during a key step in the cell division process. When the gene is mutated, it loses its braking function and uncontrolled cell growth may result. The p16 gene is the one of the most important tumor suppressors discovered to date and is involved in approximately half of all cancers. "MELARIS(TM) is the fourth predictive medicine product utilizing Myriad's highly accurate, high-throughput, DNA sequencing technology," said Gregory Critchfield, M.D., President of Myriad Genetic Laboratories, Inc. "This new test will provide the same reference standard quality test result to researchers and clinicians in the field of skin cancer that has previously been achieved in breast cancer, ovarian cancer, colon cancer and uterine cancer with Myriad's existing cancer predictive medicine products." Myriad discovered that inherited mutations in the p16 gene could dramatically increase an individual's risk of developing melanoma. More than 250 research studies have since investigated and confirmed the association between mutations in the p16 gene and melanoma. Individuals who carry a mutation in the p16 gene, resulting in a positive MELARIS(TM) test, have an estimated lifetime risk that is more than 50 times higher than the risk for those in the general population. With such important healthcare implications, the wide availability of the MELARIS(TM) test is expected to provide a major step forward in the care of individuals at increased risk of melanoma. Prevention of melanoma is the goal of the MELARIS(TM) predictive medicine product. Melanoma is lethal in 86% of cases in which it has spread to other sites in the body. When diagnosed early, melanoma patients have a survival rate of better than 90%. Patients identified at high risk may be placed on a regular schedule of office visits to check for changing moles or other early signs of disease. This process of frequent surveillance along with the removal of suspicious moles and lesions can often prevent melanoma. Melanoma is a serious health problem in the United States. Over 51,000 patients will be diagnosed with melanoma in the year 2001. Even more startling is the rapid increase in the number of melanoma cases per year. Melanoma is increasing at a rate of over 4% per year, and has become one of the fastest growing cancer types in the United States. Myriad believes that approximately 10% of these cases will have a strong family history of the disease. Individuals with a family history of melanoma should discuss the benefits of MELARIS(TM) with their physician. Myriad will begin accepting samples for testing nationwide in November, 2001. The MELARIS(TM) predictive medicine test will be sold in the United States by Myriad's existing 75-person oncology product sales force. Worldwide product rollout of the MELARIS(TM) predictive medicine test will follow its introduction in the United States. Myriad has been awarded 12 U.S. patents on the p16 gene. Fred